Business context and reporting period
ZIOPHARM Oncology, Inc. filed this unaudited Form 10-Q for the quarter ended March 31, 2016. The company was a development-stage biopharmaceutical business focused on cancer immunotherapies and had no approved products. The request metadata names Alaunos Therapeutics, Inc.; the filing itself identifies ZIOPHARM Oncology, Inc., a discrepancy investors should verify.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 or comparison |
|---|---|---|
| Research contract revenue | $1.969 million | $0.272 million |
| Research and development expense | $10.199 million | $74.249 million |
| General and administrative expense | $3.810 million | $4.250 million |
| Net loss | $12.019 million | $78.231 million |
| Net loss per share, basic and diluted | $0.09 | $0.69 |
| Cash used in operating activities | $16.079 million | $9.717 million |
| Cash and cash equivalents, quarter-end | $124.846 million | $140.717 million at December 31, 2015 |
| Working capital, quarter-end | $123.1 million | $134.4 million at December 31, 2015 |
Total assets were $141.682 million and total liabilities were $63.869 million at March 31, 2016. The balance sheet reports no borrowings or other interest-bearing debt; liabilities primarily included deferred collaboration revenue and operating accruals. Gross margin is not separately reported. Operating expenses substantially exceeded revenue, consistent with the company’s research-stage operations.
Material changes versus the prior comparable period
- Revenue rose by $1.697 million, primarily from recognizing $1.6 million of Ares Trading collaboration revenue.
- R&D expense fell by $64.050 million, principally because Q1 2015 included a one-time $67.3 million noncash charge for shares issued to MD Anderson under a license agreement. Excluding that charge, the company said current-period R&D spending increased, including a $4.0 million increase in discovery and nonclinical activities.
- Net loss narrowed by $66.212 million, largely reflecting the absence of the prior-year MD Anderson charge rather than a comparable reduction in ongoing program costs.
- Operating cash use increased by $6.362 million. The filing attributes this mainly to prepayments to MD Anderson, deferred-revenue drawdowns, higher stock-based compensation, and changes in operating assets and liabilities.
- Q1 2015 financing cash inflows included approximately $94.3 million from a public offering; Q1 2016 financing cash inflows were $0.365 million.
Outlook, risks, contingencies, and unusual items
- Management expected existing cash resources to fund operations into the fourth quarter of 2017, based on current development plans. It also said additional financing would be needed for longer-term plans, with no committed source of additional capital and no assurance financing would be available on acceptable terms.
- Planned 2016 milestones included updates on the glioblastoma and breast cancer studies, a planned CAR T-cell study for myeloid malignancies in the second half of 2016, a planned off-the-shelf NK-cell Phase 1 study for AML, and additional preclinical work. These were expectations, not guaranteed outcomes.
- The company reported $36.616 million in contractual obligations, including $30.5 million in royalty and license fees and $5.116 million in operating leases. The MD Anderson research arrangement required funding of $15 million to $20 million annually for three years; the company made a $3.75 million quarterly payment in Q1.
- Solasia initiated a pivotal darinaparsin trial on March 28, triggering a $1.0 million milestone receivable and an equivalent amount payable to MD Anderson; the filing says the transaction was reported net in the income statement. The company stated it would receive reimbursement for the license payment.
- Predictive Therapeutics was in default on $311,000 of payments and expense reimbursements related to palifosfamide transition services. ZIOPHARM had assigned its palifosfamide development and license obligations to Predictive, except for a specified outstanding stock option obligation.
- Key risks included clinical and regulatory uncertainty, cash needs and potential dilution, dependence on Intrexon and MD Anderson licenses and collaboration arrangements, manufacturing and intellectual-property risks, competition, and the challenges of novel gene- and cell-therapy approaches. Management reported no material subsequent events and no legal matters it believed could materially adversely affect the company.
Important facts for investors to verify
- Confirm the issuer identity: the supplied metadata says Alaunos Therapeutics, while this 2016 filing names ZIOPHARM Oncology, Inc.
- Assess whether the stated cash runway into Q4 2017 remains credible given the $16.1 million quarterly operating cash outflow, planned clinical expansion, and MD Anderson funding commitments.
- Separate the prior-year one-time $67.3 million license charge from recurring R&D spending when evaluating the large year-over-year improvement in net loss.
- Check progress and results against the disclosed 2016 clinical and preclinical milestones, and whether the planned trials proceeded on schedule.
- Monitor collection of the $311,000 due from Predictive and the accounting and reimbursement treatment of the Solasia/MD Anderson milestone.
- Review the terms and remaining duration of collaboration revenue recognition, license obligations, and any future financing or dilution.